Heart Failure with preserved Ejection Fraction (HFpEF) affects between 1.1-5.5% of the general population, with a prevalence of > 10% in older adults (> 75 years of age). Patients with HFpEF suffer from significant morbidity and mortality, however traditional therapies used to manage Heart Failure with reduced Ejection Fraction (HFrEF), have failed to reduce morbidity or mortality in these patients. Recently, mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and angiotensin receptor blocker neprilysin inhibitors (ARNI) have demonstrated benefits in this population, but limitations in data pose questions regarding application to routine patient care. Further understanding related to patient selection, safe initiation and monitoring, and considerations for shared-decision making discussions (e.g., cost and adherence) is important for adequate therapy optimization, particularly in ambulatory settings and with older adult patients. This session will discuss an initial overview of HFpEF, the "traditional" approach to management, and gaps in patient care; next an interactive discussion of recently evaluated entities for HFpEF, including MRA, ARNI and SGLT2 inhibitors; and finally, a case-based format, allowing both audience and panel of clinical experts to engage in discussion and debate. The BCACP/BCGP Clinical Sessions are part of the professional development program for the recertification of board-certified ambulatory care pharmacists and/or geriatric pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCACP and/or BCGP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCACP/BCGP Clinical Sessions posttests will be available on December 14, 2022, at www.accp.com/myaccount to anyone who has purchased access to the BCACP and/or BCGP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 18, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 12, 2023.